Seattle Genetics Stock News

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management.

Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he increased his stake in IDEAYA Biosciences Inc. ( IDYA , Financial) by 52.12%.

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management.

Seagen Inc (SGEN) shares closed today at 1.9% above its 52 week low of $118.00, giving the company a market cap of $22B. The stock is currently down 22.2% year-to-date, down 24.2% over the past 12 months, and up 83.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.4%. Trading Activity Trading volume this week was 52.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 4.0% lower than its 5-day moving average, 7.8% lower than its 20-day moving average, and 22.5% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 62.4% The company's stock price performance over the past 12 months lags the peer average by 2466.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

These stocks are already down more than 20% this year.

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (enfortumab vedotin-ejfv) in muscle-invasive bl

Seagen Inc (SGEN) shares closed today 11.7% lower than it did at the end of yesterday. The stock is currently down 8.5% year-to-date, down 19.5% over the past 12 months, and up 125.1% over the past five years. Today, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%. Trading Activity Shares traded as high as $143.42 and as low as $118.00 this week.Shares closed 35.2% below its 52-week high and 3.3% above its 52-week low.Trading volume this week was 36.5% higher than the 10-day average and 56.0% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -15.8% The company's stock price performance over the past 12 months lags the peer average by -331.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

U.S. indices were trading lower Thursday following comments from St. Louis Fed President James Bullard indicating he favors a 1% rate increase by July 1. Investors also continue to react to worse-than

Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.

Investors aren't happy about disappointing forward guidance.

The Nasdaq 100 NDX, -2.08% slumped 1.7% in afternoon trading Thursday, with only 17 of its components gaining ground, after the technology-friendly index ran up 3.3% over the past two days. The index'

Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc

Macquarie boosted the price target on Twilio Inc. (NYSE: TWLO) from $281 to $306. Twilio shares jumped 20.4% to $243.23 in pre-market trading. Barclays raised Motorola Solutions, Inc. (NYSE: MSI)